Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Molecular Cytogenetics

Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints

Leukemia volume 12, pages 1895–1902 (1998)Cite this article

Abstract

The t(9;11)(p22;q23) is the most common chromosomal translocation in topoisomerase II inhibitor therapy-related acute myeloid leukemia (tAML). This translocation fuses the MLL and AF9 proto-oncogenes producing a novel chimeric protein. In order to gain insight into the mechanism generating the t(9;11) and to clarify the role topoisomerase II inhibition may play in that mechanism we have cloned and sequenced the breakpoints from four tAML patients with the t(9;11). This sequence analysis identifies topoisomerase II consensus binding sequences near or at the chromosome 11 and chromosome 9 breakpoints in all four patients. One patient also had the consensus binding sequence for the TRANSLIN DNA-binding protein at the 9p22 and 11q23 breakpoints. Our results further support a direct role for topoisomerase II in the genesis of these tAML translocations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Author notes

  1. M Atlas

    Present address: Department of Pediatrics, Division of Oncology, Columbia University, New York, NY, USA

  2. D Burian

    Present address: Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, USA

Authors and Affiliations

  1. Department of Pediatrics, Section of Hematology-Oncology, Northwestern Univerity, Chicago, IL, USA

    M Atlas & E Schmidt

  2. Department of Pathology, St Judes Childrens Research Hospital, Memphis, TN, USA

    D Head & F Behm

  3. Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA

    NJ Zeleznik-Le

  4. Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, USA

    BA Roe & D Burian

  5. Department of Pathology, University of Chicago, Chicago, IL, USA

    PH Domer

Authors
  1. M Atlas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Head
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Behm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. NJ Zeleznik-Le
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. BA Roe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Burian
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. PH Domer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Atlas, M., Head, D., Behm, F. et al. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia 12, 1895–1902 (1998). https://doi.org/10.1038/sj.leu.2401223

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401223

Keywords

This article is cited by

Search

Advanced search

Quick links